Under 10% of individuals who could benefit from obesity jabs like Wegovy are able to get them, caution the World Health Organization as it releases its initial recommendations on the drugs.
Given in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for broader and more equitable availability to this class of drugs.
Based on forecasts, more than two billion are projected to be obese by 2030 if no action is taken.
"Our latest guidelines recognises that excess weight is a chronic disease that can be treated with comprehensive and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are significant obstacles to broad availability to the injections that can assist patients in reducing substantial weight, notes the organization.
GLP-1 Therapy Scarcity
Despite the present most optimistic outlook, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – less than 10% of the global need, per the health organization.
The guideline urges nations and manufacturers to expand access, through measures like licensing agreements.
Exclusive production rights on the active ingredient – the primary component of the drug Wegovy – is due to expire in several nations in 2026.
The Way Obesity Drugs Operate
These medications imitate a natural hormone to delay gastric emptying, curb appetite and increase satiety so users eat less.
Individuals typically see weight reduction in the initial weeks of starting on the once-weekly jabs.
Studies points to users may see weight return after a year of stopping the treatment, as their normal appetite come back.
To be carrying excess weight raises your chance for experiencing medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight concerns people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.
